The OSBPL10 Knockout Raji Polyclonal Cells constitute a CRISPR/Cas9-mediated gene disruption model of oxysterol-binding protein-like 10 (OSBPL10) in a polyclonal Raji B lymphocyte background. This heterogeneous knockout pool offers a loss-of-function system suitable for studying OSBPL10-dependent cellular processes without the limitations of clonal selection, preserving biological variability relevant to population-level assays.
The Raji host cell line is an Epstein-Barr virus (EBV)-positive B lymphocyte model derived from a Burkitt??s lymphoma patient. It is widely employed to investigate EBV latency, B cell receptor signaling, apoptosis regulation, and lymphomagenesis. Its rapid proliferation and well-characterized signaling networks make Raji cells an ideal platform for examining lipid-regulated survival pathways in a malignant B cell context.
OSBPL10 functions as an oxysterol sensor and lipid transfer protein at endoplasmic reticulum?Cplasma membrane contact sites. Upon binding 25-hydroxycholesterol, OSBPL10 engages VAPA and VAPB to facilitate non-vesicular cholesterol transport, promoting plasma membrane cholesterol accumulation and activation of PI3K/AKT signaling. This cascade enhances cell proliferation and suppresses apoptosis, linking lipid homeostasis to oncogenic growth. The protein network includes OSBP, CERT, and the LDL receptor, with upstream input from oxysterols and downstream influence on lipid droplet dynamics and cholesterol efflux.
In the Raji lymphoma background, OSBPL10 disruption is particularly relevant for dissecting the interplay between cholesterol metabolism and B cell survival. Aberrant lipid trafficking contributes to the malignant phenotype, and OSBPL10-mediated AKT activation may cooperate with EBV latent gene expression to sustain lymphomagenesis. Thus, this knockout model allows direct interrogation of whether OSBPL10 loss alters lipid raft composition, AKT phosphorylation, or sensitivity to apoptotic stimuli in a B lymphoma setting.
Researchers can employ this product in a range of assays including Western blotting, RT-qPCR, RNA-seq, immunofluorescence-based lipid distribution analysis, and flow cytometric apoptosis assessment (Annexin V/PI). Co-immunoprecipitation with VAPA and phospho-AKT ELISA enable mechanistic dissection of OSBPL10 interactions. Functional studies may also incorporate cholesterol efflux and MTS proliferation assays to characterize metabolic rewiring. Applications extend to cancer cell biology, lipid metabolism, ORP family functional genomics, B cell lymphoma research, and early-stage drug target validation. For further details, please contact Ascent Research.
